Meir Rinde

Since the approval of sipuleucel-T for the treatment of minimally symptomatic metastatic castration-resistant prostate cancer in 2010, barriers to administration and the approval of competing drugs has tampered wide adoption of its use.

The treatment paradigm for HER2-positive breast cancer may be reshaped over the next several years, as head-to-head studies comparing new agents to the current standard of care begin to yield results, said Sara A. Hurvitz, MD.

Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.